Exact Sciences Corp - Company Profile
Powered by 
All the data and insights you need on Exact Sciences Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date Exact Sciences Corp Strategy Report
- Understand Exact Sciences Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Business Description
Exact Sciences Corp (Exact Sciences) is a molecular diagnostic company, which focuses on the early detection and prevention of cancers. The company uses its proprietary stool-based DNA (sDNA) screening technology to identify the presence of cancer and pre-cancer. Its flagship product Cologuard is a non-invasive colon cancer screening test.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Exact Sciences focuses on the development of new products and enhancement of existing products to address new cancer areas, including screening and prevention, risk assessment, early disease diagnosis, adjuvant and neoadjuvant disease treatment, and metastatic disease treatment selection and patient monitoring. Major platforms include Oncotype IQ genomic intelligence platform. In FY2022, the company spent US$393.4 million on its R&D activities, which as a percentage of revenue stood at 18.9%. As of December 2022, it had 166 issued patents in the US and 824 issued patents outside the US. The company also has several pending patent applications in the US and in other countries. The company also has collaboration with Mayo Clinic in Rochester, Minnesota.
Product Categories
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers Oncotype DX gene expression tests for prostate, breast, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect test, a liquid-based test designed to guide treatment decisions for advanced stage prostate cancer. The company commercializes Oncotype DX tests directly and also through exclusive distribution agreements internationally. It includes laboratory service revenue from global Oncotype DX products. Views acquisitions as a critical factor for growth for the category.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Offers screening tests that use a multi-target approach for the detection of DNA and hemoglobin biomarkers related to colorectal cancer and pre-cancer. Major products include Cologuard test, a non-invasive stool-based deoxyribonucleic acid (DNA) screening product. Focus on the development of new products and enhancement of existing products in new cancer areas. It also aims at expanding primary care sales force to promote Cologuard across the US.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer